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Sir
Since a second oestrogen receptor (ER), ERb was identiﬁed in the
middle of the 1990s (Mosselman et al, 1996), there has been much
effort directed into trying to deﬁne its biological role in hormone
sensitive tissue such as the mammary gland, particularly at the
protein level. In a recent issue of British Journal of Cancer, Saun-
ders et al (2002) reported immunohistochemical detection of
ERb in 51 breast tumours. In their study cohort, almost all samples
were positive for ERb (48 out of 51; 94%). In an earlier issue of
British Journal of Cancer (Skliris et al, 2001), we too reported
immunohistochemical detection of ERb in a similar sized cohort
of 63 breast tumours, and showed much less positive nuclear
ERb immunoreactivity (48 out of 65; 74%). It is interesting to note
that both studies used an identical scoring system, based on asses-
sing both staining intensity (scored 0–3) and percentage positivity
(scored 0–5), which generates a numerical score ranging from 0–
8 (Allred et al, 1998). In both instances, a score of 42 was consid-
ered positive.
Why such divergent results in such similar sized cohorts? A
Scottish–English patient bias seems unlikely (but has not been
excluded!). However, it may be pertinent that each study used
monoclonal antibodies directed against different parts of ERb.
More recent work from our group has shown a considerable
variation in the efﬁcacy of distinct ERb antibodies to detect recep-
tor protein under different applications (Skliris et al, 2002) and
Saunders also makes this point in her penultimate paragraph,
when referring to other published immunohistochemical studies.
It is also perhaps important to remind ourselves that the appro-
priate threshold for scoring a tumour as ‘positive’ for ERb will
remain unclear until immunohistochemical expression can be
correlated with endocrine response in the clinical context. ERb
may well be an important player in the ER signalling cascade
but until there is a recognised consensus on the best way to
measure it in a clinically meaningful way, the waters will surely
remain muddied.
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